hospitalisation.2"
In recent years there has been an increased understanding of the interactions between the organism and the host, and specifically between the pneumococcus and the host, both in terms ofhow virulence factors of the organism contribute to disease pathogenesis and how the host's response to infection, through the release of cytokines, may be deleterious. What are the prospects for using this knowledge to address these outstanding problems?
Immunotherapy Cytokines are low molecular weight hormone-like polypeptides produced during immune reactions which are capable of mediating pathological as well as beneficial effects. Recombinant forms ofseveral cytokines, and monoclonal antibodies raised against them, are now available and, as their roles in disease processes are beginning to be understood, their therapeutic potential is being considered. One area in which substantial understanding has been gained of the harmful consequences of cytokines induced by host-organism interactions is septic shock and the adult respiratory distress syndrome (ARDS). There is strong experimental evidence that tumour necrosis factor (TNF), interleukin (IL)-1 and IL-6 play an important role in the pathogenesis of these conditions,5-7 although trials of anti-TNF monoclonal antibody and IL-1 receptor antagonists in patients suffering from these conditions have so far been disappointing. 89 Nevertheless, there is still considerable optimism that more targeted studies may prove beneficial in selected patients. Although the patients in these studies were acutely ill, and some had pneumonia, the results cannot be extrapolated to pneumococcal infection, for most of the patients were infected with Gram negative bacteria. Furthermore, our understanding of the relevance of these studies is limited by our lack of understanding of pneumococcal septicaemia, in particular the extent to which ARDS or classical septic shock complicate this condition.
Only a limited number of studies have specifically examined the role of cytokines in pneumonia. A recent study by Moussa and colleagues'0 measured plasma IL-6 and TNFoa levels in patients admitted to hospital with community acquired pneumonia. They found raised levels of these cytokines in a percentage of the patients at some stage in their illness but observed little correlation with the outcome ofinfection. Marik et all' also found raised levels of serum TNFot in inpatients with severe community acquired pneumonia but, in this case, in all patients studied. The levels remained stable over the first 12 hours of admission, were unaffected by antibiotics and, again, gave no prediction of outcome, unlike the APACHE II (disease severity) score. In contrast, two studies by Chollet-Martin and coworkers did find a positive correlation between cytokine levels and patient outcome.'213 These studies principally concerned cytokine levels in patients with ARDS but included patients with pneumonia as a control group. Plasma levels of TNFx, IL-6, and IL-8 were raised in patients with pneumonia compared with controls. Levels were not as high as in patients with ARDS (without pneumonia) but were greatest in patients with both ARDS and pneumonia. In the overall patient group significantly higher levels of plasma IL-6, bronchoalveolar lavage fluid IL-8, and a trend towards higher plasma TNFot were found in the patients who died. In addition, lung injury scores were positively correlated with plasma TNFa and IL-6 amongst the patients with pneumonia. Thus there is some evidence of raised plasma levels of TNFoa, IL-6 and IL-8 in patients with pneumonia, but the pathogenic and prognostic implications of their presence is not clear.
Several factors may contribute to the differences between these results. Firstly, the time point at which samples are obtained is very likely to be critical to the outcome of a study as cytokines are subject to regulatory mechanisms; thus non-elevated TNF levels, for example, may result from missing the peak of production and do not necessarily indicate that the cytokine is unimportant in disease pathogenesis. Secondly, the difficulties of obtaining accurate and meaningful plasma cytokine measurements are increasingly being recognised;'4 15 
Conclusions
It is too early to know whether cytokines will have a place in the management of pneumococcal infection. There are many potential pitfalls in disturbing the intricate counterbalances of the immune system, but this is a rapidly developing field in which advances can be expected, and it is possible that a small number of selected patients may eventually be shown to benefit from this treatment. However, reliable cytokine measurements which can be interpreted with expertise will need to be available to identify the patients who may benefit. In contrast, vaccination is a well established form of immunological intervention, and there are real prospects of the pneumococcal vaccine being improved. Immunisation offers the only realistic hope of reducing the incidence and overall burden of pneumococcal disease, although concerted efforts will be needed to implement and assess immunisation programmes. New developments in vaccination should not be neglected in the rush to find a use for cytokines.
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